Inovelon® (Rufinamide) Oral Suspension Formulation Launched in Portugal
HATFIELD, England, December 17, 2013
HATFIELD, England, December 17, 2013 /PRNewswire/ --
PRESS RELEASE NOT FOR U.S. MEDIA
Child friendly formulation will help treatment of orphan syndrome LGS, a
severe form of childhood epilepsy
Inovelon ^® (rufinamide) oral suspension for adjunctive (add-on) treatment of
seizures associated with Lennox-Gastaut syndrome (LGS) in children four years
and older has launched in Portugal. ^ The new formulation of the orphan
drug has been developed as a child friendly drinkable liquid to aid the
administration of treatment.
"The availability of the suspension formulation of rufinamide in Portugal will
potentially help young patients adhere better to treatment, which may help
improve outcomes in the management of this severe and highly debilitating
condition," commented Dr. Pedro Cabral, Neuropaediatrician, Director Clinico
do CADIn, Cascais, Portugal.
LGS is one of the most severe forms of childhood epilepsy and accounts for 5%
of epilepsy in children, ^ with the peak of onset at between ages three and
five. ^ LGS is characterised by multiple daily seizures and people with the
condition can have up to 70 seizures a day. ^ Most children with LGS also
experience developmental problems leading to impaired intellectual function
and behavioural issues. ^ LGS is one of the most drug-resistant forms of
childhood epilepsy and effective management of the condition is often very
difficult, reiterating the importance for children to adhere to treatment
protocols. Results from a double-blind, randomised, placebo-controlled trial
of rufinamide demonstrate a reduction in tonic-atonic ('drop attack') seizure
frequency of 42.5% compared to placebo. ^
"We are pleased to announce the launch of the Inovelon oral suspension
formulation in Portugal for those with LGS, and hope that it may help improve
treatment compliance in children and young people with this severe form of
epilepsy," commented Miguel Marcão, Managing Director for Spain and Portugal,
Eisai Farmaceutica Lda. "Eisai is working closely with epilepsy centres across
the country to ensure the new treatment is available to those who need it as
soon as possible, in line with our ongoing commitment to improve the lives of
people with epilepsy and those of their families."
The rufinamide oral suspension formulation is identical in preparation to the
currently marketed rufinamide tablet on a milligram per milligram basis.
Rufinamide oral suspension received positive CHMP opinion in September 2011
and formal EMA approval was granted in November 2011. The preparation was
launched in Germany in March 2012.
The development of an oral suspension formulation of rufinamide demonstrates
Eisai's commitment to the therapeutic area of epilepsy and further exemplifies
the company's human health care (hhc ) mission to address the diversified
needs of and increase the benefits provided to patients and their families
Notes to Editors
About Inovelon ^® (rufinamide)
Rufinamide is a triazole derivative that is structurally unrelated to
currently marketed antiepileptic drugs (AEDs). It is believed to regulate the
activity of sodium channels in the brain which carry excessive electrical
charges. The agent was approved for adjunctive therapy for seizures associated
with LGS in Europe (under the brand name Inovelon) in 2007. ^[ ^1] Rufinamide
is available as film-coated tablets containing 100mg, 200mg, and 400mg
rufinamide and as a 40 mg/ml oral suspension.
The film-coated formulation of rufinamide was first launched in Europe in May
2007 and is now available in 19 European countries. Rufinamide oral suspension
received EMA approval in November 2011.
About Lennox-Gastaut Syndrome
Lennox-Gastaut syndrome, or LGS, is a rare form of childhood-onset epilepsy
which usually appears between the ages of three and five. ^[ ^3] The syndrome
is characterised by frequent seizures and multiple seizure types, behaviour
issues, mental retardation, regression, and a resistance to medications or
therapies. ^[ ^2]
Epilepsy is one of the most common neurological conditions in the world,
affecting approximately eight in 1,000 people in Europe, and an estimated 50
million people worldwide. ^ ^, ^ Epilepsy is a chronic disorder of the
brain that affects people of all ages. It is characterised by abnormal
discharges of neuronal activity causing seizures. Seizures can vary in
severity, from brief lapses of attention or jerking of muscles, to severe and
prolonged convulsions. Depending on the seizure type, seizures may be limited
to one part of the body, or may involve the whole body. Seizures can also vary
in frequency from less than one per year, to several per day. Epilepsy has
many possible causes but often the cause is unknown.
About Eisai EMEA in Epilepsy
Eisai is committed to developing and delivering highly beneficial new
treatments to help improve the lives of people with epilepsy. The development
of AEDs is a major strategic area for Eisai in Europe, the Middle East,
Africa, Russia and Oceania (EMEA).
In the EMEA region, Eisai currently has four marketed treatments including:
*Fycompa ^® (perampanel) for use as an adjunctive treatment for partial
onset seizures, with or without secondarily generalised seizures, in
patients with epilepsy aged 12 years and older
*Zonegran ^® (zonisamide) as monotherapy in the treatment of partial
seizures, with or without secondary generalisation, in adults with newly
diagnosed epilepsy and as adjunctive therapy in the treatment of partial
seizures, with or without generalisation, in adults, adolescents and
children aged six years and above. (Zonegran is under license from the
originator Dainippon Sumitomo Pharma)
*Zebinix ^® (eslicarbazepine acetate) as adjunctive therapy in adult
patients with partial onset seizures, with or without secondary
generalisation. (Zebinix is under license from BIAL)
*Inovelon ^® (rufinamide) for the adjunctive treatment of seizures
associated with Lennox-Gastaut Syndrome in patients >4 years (Rufinamide
was originally developed by Novartis)
Eisai is one of the world's leading research and development (R&D) based
pharmaceutical companies and we define our corporate mission as "giving first
thought to patients and their families and to increasing the benefits health
care provides," which we call human health care ( hhc ).
Eisai concentrates its R&D activities in three key areas:
*Neuroscience, including: Alzheimer's disease, epilepsy, pain and weight
*Oncology including: anticancer therapies; tumour regression, tumour
suppression, antibodies, etc.
*Vascular/Immunological reaction including: thrombocytopenia, rheumatoid
arthritis, psoriasis, inflammatory bowel disease
With operations in the U.S., Asia, Europe and its domestic home market of
Japan, Eisai employs more than 10,000 people worldwide. From its EMEA
Knowledge Centre in Hatfield, UK, Eisai has recently expanded its business
operations to include Europe, the Middle East, Africa, Russia and Oceania
(EMEA). Eisai EMEA has sales and marketing operations in over 20 markets,
including the United Kingdom, France, Germany, Italy, Spain, Switzerland,
Sweden, Ireland, Austria, Denmark, Finland, Norway, Portugal, Czech Republic,
Slovakia, the Netherlands, Belgium, Russia and the Middle East.
For further information please visit our web site http://www.eisai.co.uk
^[1 ^] SPC Inovelon (updated August 2013). Available at:
[Last accessed November 2013]
^[2 ^] Tyagi, S. et al . International Journal of Pharma and Bio Sciences.
Pharmacological Management of Lennox-Gastaut Syndrome - a difficult to treat
form of childhood epilepsy: an overview. 2012. Available at:
http://www.ijpbs.net/issue-3/82.pdf [Last accessed November 2013]
^[3 ^] Epilepsy Foundation. Lennox-Gastaut syndrome. Available at:
[Last accessed November 2013]
^[4 ^] Special Child. Lennox-Gastaut syndrome. Available at:
http://www.specialchild.com/archives/dz-017.html [Last accessed November 2013]
^[5 ^] US National Library of Medicines. Lennox-Gastaut syndrome. Available
at: http://ghr.nlm.nih.gov/condition/lennox-gastaut-syndrome [Last accessed
^[6 ^] Glauser, T, et al . Rufinamide for generalized seizures associated with
Lennox-Gastaut syndrome. Neurology. 2008;70:1950-1958.
^[7 ^] Epilepsy in the WHO European Region: Fostering Epilepsy Care in Europe.
accessed November 2013]
^[8 ^] Pugliatti M, et al . Epilepsia 2007: 48(12) 2224-2233.
Date of preparation: December 2013
Job code: Inovelon-UK2287
Contact: Media Enquiries: Eisai Europe Ltd, Cressida Robson / Charlotte
Andrews, +44(0)7908-314-155/+44(0)7947-231-513, Cressida_Robson@eisai.net,
Charlotte_Andrews@eisai.net; Tonic Life Communications, Frances Murphy/Nicola
Lilley, +44(0)207-798-9262 /+44(0)207-798-9905, firstname.lastname@example.org,
Press spacebar to pause and continue. Press esc to stop.